文献速递MDS 与骨髓增殖性肿瘤白血病造血干细胞移植与细胞治疗

慢性粒单核细胞白血病需专属临床试验:认知提升与新疗法涌现

Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia.
PubMed 文献 · Leukemia · 2021-06-26

慢性粒单核细胞白血病(CMML)兼具骨髓增生异常综合征(MDS)与骨髓增殖性肿瘤(MPN)特征,中位总生存仅2-3年,急性白血病转化风险15-30%。专属临床试验缺乏使治疗多借鉴MDS与MPN方案,现有标准治疗为羟基脲、低甲基化药物(HMA)和异基因造血干细胞移植,HMA未实质改变疾病自然病程。综述聚焦CMML新兴靶向与联合治疗策略,并讨论合理设计疾病修饰疗法的方向。

要点

  • CMML中位总生存仅2-3年,急性白血病转化风险15-30%。
  • 专属临床试验缺乏,治疗范式多借鉴MDS与MPN。
  • HMA未实质改变自然病程,异基因移植仍是唯一潜在治愈手段。

核心结论

  • CMML亟需专属临床试验,有效治疗可能需靶向多通路的联合方案。

研究设计与样本

  • 综述,聚焦CMML近期治疗进展与创新策略,包括全局性与分子靶向方法。

主要发现

  • CMML中位总生存仅2-3年,急性白血病转化风险15-30%。
  • 已获批药物为HMA,包括阿扎胞苷、地西他滨及口服地西他滨联合cedazuridine。
  • HMA治疗未实质改变CMML自然病程。
  • 超过25种治疗药物正在CMML及其他髓系恶性肿瘤的1或2期临床试验中评估,常联合HMA骨架。
  • sotatercept、ruxolitinib、lenzilumab和tagraxofusp等新药在CMML中显示有前景的临床疗效。

临床怎么用

  • 标准治疗仍依赖羟基脲、HMA和异基因造血干细胞移植,移植是唯一潜在治愈手段。
  • 新兴药物多在HMA骨架基础上联合使用,有效方案可能需多通路联合。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder with overlapping features of myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN). Median overall survival of this aggressive myeloid malignancy is only 2-3 years, with a 15-30% risk of acute leukemic transformation. The paucity of clinical trials specifically designed for CMML has made therapeutic management of CMML patients challenging. As a result, treatment paradigms for CMML patients are largely borrowed from MDS and MPN. The standard of care still relies on hydroxyurea, hypomethylating agents (HMA), and allogeneic stem cell transplantation, this latter option remaining the only potentially curative therapy. To date, approved drugs for CMML treatment are HMA, including azacitidine, decitabine, and more recently the oral combination of decitabine and cedazuridine. However, HMA treatment does not meaningfully alter the natural course of this disease. New treatment approaches for improving CMML-associated cytopenias or targeting the CMML malignant clone are emerging. More than 25 therapeutic agents are currently being evaluated in phase 1 or phase 2 clinical trials for CMML and other myeloid malignancies, often in combination with a HMA backbone. Several novel agents, such as sotatercept, ruxolitinib, lenzilumab, and tagraxofusp have shown promising clinical efficacy in CMML. Current evidence supports the idea that effective treatment in CMML will likely require combination therapy targeting multiple pathways, which emphasizes the need for additional new therapeutic options. This review focuses on recent therapeutic advances and innovative treatment strategies in CMML, including global and molecularly targeted approaches. We also discuss what may help to make progress in the design of rationally derived and disease-modifying therapies for CMML.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Renneville A, Patnaik MM, Chan O, et al. Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia. Leukemia. 2021. PMID: 34175902. doi:10.1038/s41375-021-01330-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。